Hypertrophic cardiomyopathy:a paradigm for myocardial energy depletion.

Hypertrophic cardiomyopathy:a paradigm for myocardial energy depletion.

Genetic analysis of hypertrophic cardiomyopathy (HCM), a mendelian form of cardiac hypertrophy, indicates that the primary defect is in sarcomeric function. However, the initial proposal that depressed myocardial contraction leads to a 'compensatory' hypertrophy has proven inconsistent wit...

Bibliografski detalji
Glavni autori:	Ashrafian, H, Redwood, C, Blair, E, Watkins, H
Format:	Journal article
Jezik:	English
Izdano:	2003

Slični predmeti

Myocardial dysfunction in hypertrophic cardiomyopathy.
od: Ashrafian, H, i dr.
Izdano: (2001)

Ascertainment strategies and genotype:phenotype correlations in hypertrophic cardiomyopathy.
od: Blair, E, i dr.
Izdano: (2003)

Metabolic perturbations in the pathogenesis of hypertrophic cardiomyopathy
od: Ashrafian, H, i dr.
Izdano: (2005)

The genetics of hypertrophic cardiomyopathy: Teare redux.
od: Watkins, H, i dr.
Izdano: (2008)

Functional analysis of hypertrophic cardiomyopathy missense mutations in the light meromyosin region of beta myosin heavy chain
od: Redwood, C, i dr.
Izdano: (2003)

Inherited cardiomyopathies.
od: Watkins, H, i dr.
Izdano: (2011)

Inherited cardiomyopathies.
od: Watkins, H, i dr.
Izdano: (2011)

Disease pathways and novel therapeutic targets in hypertrophic cardiomyopathy.
od: Ashrafian, H, i dr.
Izdano: (2011)

Mutations in the gamma(2) subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis.
od: Blair, E, i dr.
Izdano: (2001)

Mutations in the gamma2 subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis.
od: Blair, E, i dr.
Izdano: (2001)

Exercise-induced ventricular dysfunction in hypertrophic cardiomyopathy: stunning by any other name?
od: Ashrafian, H, i dr.
Izdano: (2008)

Hypertrophic cardiomyopathy mutations in the gamma 2 subunit of AMP-activated kinase suggest a central role of energy compromise in disease pathogenesis
od: Blair, E, i dr.
Izdano: (2001)

Altered regulatory properties of human cardiac troponin I mutants that cause hypertrophic cardiomyopathy.
od: Elliott, K, i dr.
Izdano: (2000)

Linked genetic modifiers in hypertrophic cardiomyopathy
od: Ektisham, J, i dr.
Izdano: (2004)

Investigation of troponin I mutations causing familial hypertrophic cardiomyopathy
od: Abdulrazzak, H, i dr.
Izdano: (2001)

Correlates of myocardial fibrosis in hypertrophic cardiomyopathy
od: Kramer, CM, i dr.
Izdano: (2018)

Effects of hypertrophic cardiomyopathy mutations in troponin I on contractility of skinned cardiac muscle fibres
od: Burton, D, i dr.
Izdano: (2002)

Early onset malignant hypertrophic cardiomyopathy caused by mutations in MYBPC3
od: Carballo, S, i dr.
Izdano: (2003)

Sudden death in hypertrophic cardiomyopathy.
od: Watkins, H
Izdano: (2000)

Altered inhibitory and troponin C-binding activities in cardiac troponin I mutants known to cause hypertrophic cardiomyopathy
od: Elliott, K, i dr.
Izdano: (2000)

Novel mutations in cardiac MYBPC3 and early onset malignant hypertrophic cardiomyopathy
od: Carballo, S, i dr.
Izdano: (2005)

Delineating the role of adenosine monophosphate (AMP)-activated protein kinase (AMP) gamma 2 subunit in hypertrophic cardiomyopathy (HCM)
od: Grignani, R, i dr.
Izdano: (2005)

Comparison of the functional effects of mutations in troponin T which cause dilated and hypertrophic cardiomyopathies
od: Robinson, P, i dr.
Izdano: (2002)

Identification of myocardial disarray in patients with hypertrophic cardiomyopathy and ventricular arrhythmias
od: Ariga, R, i dr.
Izdano: (2019)

Mutations of the light meromyosin domain of the beta-myosin heavy chain rod in hypertrophic cardiomyopathy.
od: Blair, E, i dr.
Izdano: (2002)

Novel mutations in cardiac MYBPC3 causing early onset malignant hypertrophic cardiomyopathy
od: Carballo, S, i dr.
Izdano: (2005)

Diffusion tensor magnetic resonance imaging of myocardial disarray in hypertrophic cardiomyopathy
od: Ariga, R, i dr.
Izdano: (2018)

Is DNA testing for hypertrophic cardiomyopathy cost-effective?
od: Wordsworth, S, i dr.
Izdano: (2006)

Mutations in cis can confound genotype-phenotype correlations in hypertrophic cardiomyopathy.
od: Blair, E, i dr.
Izdano: (2001)

Double mutations in CIS can confound genotype-phenotype correlations in hypertrophic cardiomyopathy
od: Blair, E, i dr.
Izdano: (2000)

Novel mutations in cardiac MYPBC3 cause early onset malignant hypertrophic cardiomyopathy (HCM)
od: Carballo, S, i dr.
Izdano: (2005)

Progression of myocardial fibrosis in hypertrophic cardiomyopathy: mechanisms and clinical implications
od: Raman, B, i dr.
Izdano: (2018)

Blunted myocardial oxygenation response during vasodilator stress in patients with hypertrophic cardiomyopathy.
od: Karamitsos, T, i dr.
Izdano: (2013)

METABOLIC ALTERATION IN HYPERTROPHIC CARDIOMYOPATHY (METAL-HCM STUDY): RANDOMISED DOUBLE BLINDED PLACEBO CONTROLLED TRIAL OF PERHEXILINE THERAPY IN PATIENT WITH HYPERTROPHIC CARDIOMYOPATHY
od: Abozguia, K, i dr.
Izdano: (2010)

Dilated and hypertrophic cardiomyopathy mutations in troponin and alpha-tropomyosin have opposing effects on the calcium affinity of cardiac thin filaments.
od: Robinson, P, i dr.
Izdano: (2007)

Impaired left ventricular energy metabolism in hypertrophic cardiomyopathy is not due to fibrosis.
od: Petersen, SE, i dr.
Izdano: (2009)

HYPERTROPHIC CARDIOMYOPATHY AND MYOCARDIAL CRYPT OF THE LEFT VENTRICLE
od: Yu. V. Frolova, i dr.
Izdano: (2017-02-01)

A novel mutation in phospholamban causes a mixed hypertrophic and dilated cardiomyopathy phenotype with autosomal dominant inheritance
od: Carballo, S, i dr.
Izdano: (2004)

Regression of dilated-hypokinetic hypertrophic cardiomyopathy by biventricular cardiac pacing.
od: Ashrafian, H, i dr.
Izdano: (2007)

DEVELOPMENT AND CHARACTERISATION OF A NOVEL KNOCK-IN MODEL OF PRKAG2 CARDIOMYOPATHY
od: Yavari, A, i dr.
Izdano: (2009)